97 results about "Adriamycinol" patented technology

The invention discloses a fluorescence ratio type carbon dot hydrogel sensor, a preparation method thereof and application of the fluorescence ratio type carbon dot hydrogel sensor in rapid detection of doxorubicin hydrochloride. The invention discloses a fluorescence ratio type carbon dot hydrogel sensor which is characterized in that 3-aminophenol is used as a carbon source, absolute ethyl alcohol is used as a solvent, carbon dots are prepared through a one-step solvent method, the carbon dots have green fluorescence, agarose is dissolved in a mixed solution of deionized water and a phosphate buffer solution to be fully dissolved, and then the carbon dots are prepared into the fluorescence ratio type carbon dot hydrogel sensor. And adding the carbon dots into the mixed solution, fully dispersing, and cooling to obtain the fluorescence ratio type carbon dot hydrogel sensor. The sensor disclosed by the invention has the characteristics of high selectivity and high sensitivity when being used for detecting doxorubicin hydrochloride, and also has the characteristics of convenience, visibility, rapidness, portability, easiness in operation and the like.

The invention discloses a single cell activity evaluation method based on cell nucleus geometric parameters and a Bayesian framework, which comprises the following steps: establishing a HeLa cell activity gradient model through adriamycin induction, carrying out cell nucleus segmentation by adopting Cell pose 3.0 and extracting 26 geometric features, screening a high-confidence sample in combination with a Bayesian deep learning framework, and evaluating the activity of a single cell according to the high-confidence sample. And constructing a multi-modal feature fusion model to integrate geometric features and deep semantic features, and finally realizing unmarked and high-precision single cell activity evaluation. The method overcomes the limitation that a traditional technology depends on biochemical markers, has the advantages of being easy and convenient to operate, high in flux and high in interpretability, and provides an innovative technical means for tumor liquid biopsy and precise medical treatment.

The invention discloses an extraction method of safflower leaf exosome-like nano-vesicles and application of the safflower leaf exosome-like nano-vesicles in preparation of drugs for preventing and treating adriamycin-induced cardiotoxicity, fresh safflower leaves are taken and cleaned, a PBS solution is added for crushing and filtering, filtrate is collected and continuously centrifuged, supernate is taken and subjected to ultracentrifugation, precipitates are collected after centrifugation, and the safflower leaf exosome-like nano-vesicles are obtained; and filtering and sterilizing by using a filter membrane to obtain the safflower leaf exosome-like nano-vesicles. The carthamus tinctorius leaf exosome-like nano-vesicles can significantly improve the heart function of doxorubicin-induced cardiotoxic mice; myocardial injury induced by doxorubicin can be repaired, and myocardial fibrosis induced by doxorubicin can be inhibited; the content of a myocardial injury marker lactic dehydrogenase in body serum can be reduced, a new treatment strategy is provided for preventing and treating adriamycin-induced cardiotoxic diseases, and the application prospect is good.

The invention discloses a 3D bio-printing sustained-release microneedle patch used after brain glioma surgery and a preparation method thereof.The microneedle patch is prepared by compounding GFD nano-enzyme and a hydrogel base material, the GFD nano-enzyme is gambogic acid-iron-adriamycin nano-enzyme, and the hydrogel base material is a hydrogel base material. The hydrogel base material is composed of photo-crosslinking gelatin (GelMA), methacrylic hyaluronic acid (HAMA), a photoinitiator and an ultraviolet absorbent, the microneedle patch is of a conical microneedle array structure, the interior of the microneedle patch is of a porous structure, and GFD nano-enzyme is evenly distributed in microneedles. The application potential of the existing 3D biological printing and nano-enzyme technology and the technical advantages of 3D biological printing are adopted, by means of the 3D biological printing technology with high-dimensional manufacturing precision, the microneedle array structure is designed and printed in a customized mode according to the irregular shape of the tumor residual cavity of a patient, complete attachment to the wall of the residual cavity is achieved, and the dead cavity effect is solved; meanwhile, the technology can accurately regulate and control the shape, the size and the drug loading capacity of the microneedle, and provides possibility for personalized treatment.

The invention relates to the technical field of liposome preparation, and particularly discloses a nano liposome and a preparation method thereof.The method comprises the steps that distearoyl phosphatidyl ethanolamine, cholesterol, hydroxyl-terminated polyethylene glycol and mPEG-Hyd-PEG-SH are dissolved in a mixed solvent, and a lipid film is formed through rotary evaporation; hydrating with a PBS (Phosphate Buffer Solution) containing ammonium sulfate, and carrying out ultrasonic treatment to obtain primary emulsion; a doxorubicin solution is added for incubation, and drug loading is completed; the CD44 antibody and the drug-loaded liposome are coupled in a catalytic system, and are homogenized by a spiral microreactor. The problems of high immunogenicity, insufficient targeting, non-uniform particle size, uncontrollable drug release and complex preparation process of the existing PEG nano-liposome are solved, and the PEG nano-liposome has the advantages of low immunogenicity, high targeting, uniform and stable particle size, drug response release and easiness in large-scale production.

The invention belongs to the technical field of medicine research, and particularly relates to application of eicosapentaenoic acid in preparation of a medicine for preventing and treating myocardial cell death and senescence induced by adriamycin. Experiments prove that a low dose (15 [mu] M) of eicosapentaenoic acid (EPA) has no obvious toxicity to H9C2 myocardial cells, and the low dose (15 [mu] M) of EPA can improve the death phenomenon of the H9C2 myocardial cells caused by adriamycin; the EPA can be used for reducing the increase of the content of beta-galactosidase in adriamycin-induced H9C2 cells. P53 and P21 related to aging are highly expressed after being treated by 0.5 uM DOX of H9C2 myocardial cells, and EPA can obviously reduce the expression of the P53 and P21. After DOX treatment, the expression of core proteins G3BP1G3BP1 and UBAP2L of stress particles in the H9C2 myocardial cells is increased, and the phenomenon can be improved by EPA (eicosapentaenoic acid). The experiments prove that eicosapentaenoic acid can improve death and aging of adriamycin-induced H9C2 myocardial cells.

The invention relates to an application of a nano antibody for blocking RSPO1-LGR4 effect in preparation of a medicine for treating cardiovascular diseases, the nano antibody is an NB21 nano antibody, and the NB21 nano antibody has an amino acid sequence as shown in SEQ ID No.12. The invention also relates to an application of the nano antibody for blocking RSPO1-LGR4 effect in preparation of a medicine for treating cardiovascular diseases. The antibody can specifically block a Wnt / beta-catenin pathway, effectively inhibit expression of proinflammatory factors and relieve inflammatory response of heart tissues, so that occurrence and development of cardiovascular diseases are intervened. The nano antibody has significant advantages in the aspects of intervention accuracy, conversion reliability and the like, and preclinical results show that the nano antibody can improve occurrence and development of ischemic cardiomyopathy; the pharmaceutical composition can be used for treating heart failure, myocarditis and adriamycin cardiomyopathy, can be expanded to systemic inflammatory diseases, realizes the trans-boundary application of one drug with multiple targets, fully verifies the anti-inflammatory effectiveness and safety through in-vivo and in-vitro experimental data, provides new targets, diagnostic tools and accurate intervention schemes for diagnosis and treatment of cardiovascular diseases and systemic inflammatory diseases, and has wide application prospects. The obvious scientific innovation significance and clinical transformation value are realized.

The invention relates to the technical field of biological medicines, in particular to an anti-tumor compound as well as a preparation method and application thereof. The nano-diamond cannot effectively kill tumor cells due to good biocompatibility, and the ferrocene with an aromatic ring structure is combined with the nano-diamond, so that a good anti-tumor effect can be fully exerted. The TAT-PEG-PLGA has the advantages that the TAT-PEG-PLGA is high in membrane penetrating capability, water solubility, biocompatibility, stability and targeting property; the TAT-PEG-PLGA with adsorption force on the surface is used for loading the ferrocene-nano-diamond and the adriamycin to obtain the anti-tumor compound, so that the ferrocene-nano-diamond and the adriamycin can effectively enter tumor cells to jointly play an anti-tumor effect. The obtained anti-tumor compound can effectively inhibit the activity of melanoma cells A375, is an effective tumor inhibitor, and can provide a new treatment strategy and choice for tumor treatment.

The method comprises the following steps: taking red ginseng, radix ophiopogonis and schisandra chinensis, carrying out water extraction and freeze drying to obtain freeze-dried powder, taking the freeze-dried powder, adding distilled water to dissolve the freeze-dried powder, adding the dissolved freeze-dried powder to a macroporous adsorption resin column, carrying out gradient elution with water, a 20% ethanol aqueous solution, a 50% ethanol aqueous solution and a 75% ethanol aqueous solution in sequence, and carrying out vacuum concentration to obtain the effective part of the pulse-activating decoction. From the beginning of sample loading, collecting every 300mL of effluent as a fraction, and collecting the fractions Fr1-Fr16; the chromatographic characteristics are analyzed, fractions with the same chromatographic characteristics are combined, the fractions Fr15-Fr16 are combined into a component yf-10, and the component yf-10 is the effective part of the pulse-activating decoction. According to the effective part disclosed by the invention, toxic parts are removed, so that H9c2 cell injury caused by adriamycin can be protected in a more effective, more stable and lower-toxicity manner, and the application of the component yf-10 in preparation of medicines for treating myocardial cell injury is prompted.

The invention discloses application of gnetum alcohol in treatment of adriamycin cardiomyopathy and diseases caused by adriamycin cardiomyopathy. The invention provides the application of the Gnetol or the pharmaceutically acceptable salt thereof in preparation of the medicine for preventing or treating diseases caused by adriamycin cardiomyopathy for the first time. The invention finds that in-vitro treatment of Gnemol can obviously inhibit rat H9C2 myocardial cell injury; when intraperitoneal injection of Gnetol is used for preventing or treating mice with adriamycin cardiomyopathy caused by intraperitoneal injection of adriamycin, the Gnetol is found to obviously relieve the adriamycin cardiotoxicity of the mice and improve the cardiac function. In-vitro and in-vivo studies find that Gnerol has a huge potential in treatment of adriamycin cardiomyopathy, and can be developed as a novel anti-adriamycin cardiomyopathy drug, thereby providing a novel approach and means for treatment of adriamycin cardiomyopathy. Meanwhile, the invention provides a brand new choice and thought for the current anti-adriamycin cardiomyopathy medicine.

The invention discloses a method for producing high-purity doxorubicin through fermentation of streptomyces peucedanum var. Peucedanum X121-56-2 and in-situ extraction of LX-20 resin, which comprises the following steps: preparing a high-density seed solution through a specific seed culture medium and a culture process, and then inoculating the high-density seed solution into a fermentation culture medium containing a composite carbon and nitrogen source and LX-20 macroporous adsorption resin; and fermenting under the conditions of controlled temperature, pH, ventilation and dissolved oxygen. In the fermentation process, adriamycin is adsorbed by LX-20 resin in situ, the yield is effectively increased, and the extraction process is simplified. The specific strain is combined with the LX-20 resin technology for the first time, the adriamycin yield can reach 530 mg / L at the maximum under the 15L tank scale, the purity of a crude product directly extracted from the resin can reach 58%, and the method has the outstanding advantages of being high in yield and purity, low in cost, easy to amplify and the like.

The application discloses application of falcarinol-7-methyl ether and derivatives thereof in preparation of medicines and functional foods for delaying aging or immune regulation. In the application, the falcarinol-7-methyl ether and derivatives thereof are derived from falcarinol-7-methyl ether, and can effectively delay replicative senescence of mesenchymal stem cells, inhibit expression of aging-related markers of mouse liver and lung induced by adriamycin, improve grip strength of the mouse, enhance muscle function, and promote proliferation of T cells separated from human peripheral blood mononuclear cells, and have an immune regulation effect. Therefore, the falcarinol-7-methyl ether and derivatives thereof have good effects of improving telomerase activity, anti-aging and immune regulation, and can be developed into anti-aging or immune regulation products.

The application discloses application of a heteroterpene compound I in preparation of a heart failure resisting drug. The heteroterpene compound I is obtained by separation and purification from a marine fungus Aspergillus terreus GZU-311, and is used to treat a mouse heart failure model induced by adriamycin or left anterior descending coronary artery ligation, and it is found that the heteroterpene compound I can improve the heart function of the mouse, reduce myocardial cell damage, inhibit myocardial connective tissue thickening, improve myocardial cell arrangement disorder, reduce inflammatory cell infiltration, and has an effect of resisting heart failure. Therefore, the application provides application of the heteroterpene compound I in preparation of a heart failure resisting drug. The application enriches drug source molecules that can be used for treating heart failure, and is helpful to development of an anti-heart failure drug and clinical treatment.

The application discloses a kind of degradable organic-inorganic hybrid nanoparticles based on calcium carbonate and preparation method thereof, the preparation method of the application uses calcium carbonate and amphiphilic block copolymer as raw material, uses amphiphilic block copolymer as organic matrix, and uses calcium carbonate aqueous solution as inorganic matrix, water-soluble drug doxorubicin hydrochloride (DOX·HCl) is wrapped in nanoparticle, and a kind of calcium carbonate-based hybrid nanoparticle is prepared using stirring mixing technology.The nanoparticle prepared by the application has moderate particle size, uniform particle size distribution, good biocompatibility and biodegradability, and is expected to become a novel drug delivery carrier.

The invention provides a traditional Chinese medicine composition and application thereof in preparation of an anti-breast cancer medicine, and relates to the technical field of biological medicine and traditional Chinese medicine pharmacy. The traditional Chinese medicine composition is prepared from the following raw materials in parts by weight: 30 to 60 parts of radix acanthopanacis semticosi, 30 to 60 parts of fructus ligustri lucidi, 30 to 60 parts of rhizoma bolbostemmae, 30 to 60 parts of caulis spatholobi, 30 to 60 parts of resina liquidamberis, 30 to 60 parts of tabasheer, 30 to 60 parts of gynura procumbens, 30 to 60 parts of aspongopus, 30 to 60 parts of pecteilis sumadai, 30 to 60 parts of thlaspi arvense, 30 to 60 parts of herba dendrobii and 10 to 30 parts of fructus ziziphi jujubae. The traditional Chinese medicine composition has the effects of strengthening the body resistance to eliminate pathogenic factors, detoxifying, removing stasis, activating blood, reducing phlegm, tonifying qi and nourishing yin. On the in-vitro level, the traditional Chinese medicine composition can remarkably inhibit proliferation, migration and invasion of BT549 and 4T1 cells at different concentrations. On the in-vivo level, the traditional Chinese medicine composition can significantly inhibit the growth speed, volume and quality of tumors, and shows an excellent tumor inhibition effect. And the anti-tumor effect of the compound can be improved after the compound is combined with adriamycin. The traditional Chinese medicine composition is expected to be further popularized and applied as an anti-breast cancer medicine.

The application belongs to the technical field of hydrogel, and particularly relates to a pH-sensitive composite hydrogel based on oxidized bacterial cellulose / cationic guar gum and a preparation method and application thereof. The application takes cationic guar gum (CGG) and oxidized bacterial cellulose (OBC) as gel wall materials, and takes adriamycin (DOX) as a loaded drug, and a CGG-OBC-DOX hydrogel is prepared through chemical cross-linking. Experimental results show that the obtained pH-sensitive hydrogel has the texture characteristics of traditional hydrogel, the internal cross-linking is strong, the structure is compact, the drug release amount at a low pH value is obviously higher than the release rate at a high pH value, the pH sensitivity and the slow release characteristics are good, the pH-sensitive hydrogel can be used for preparing an intelligent drug release system, and the hydrogel preparation does not need to add a chemical cross-linking agent, the process is simple, safe and non-toxic.

The invention discloses a folium cortex eucommiae extract and application of the folium cortex eucommiae extract in prevention and treatment of adriamycin nephropathy, and relates to the technical field of medicines, the folium cortex eucommiae extract is prepared from dried folium cortex eucommiae through water extraction, heating at 65 DEG C, ultrasonic assistance and vacuum freeze drying, LC-MS / MS analysis shows that the folium cortex eucommiae extract contains no less than 200 components, the components mainly comprise flavonoids, terpenes and phenylpropanoids, and the content of the flavonoids, the terpenes and the phenylpropanoids is no less than 100%. The folium cortex eucommiae extract has no obvious cytotoxicity to HK-2 and HBZY-1 cells under the concentration of 0-1500mu g / mL, can be used for preparing medicines for preventing and treating adriamycin nephropathy, inhibits kidney cell apoptosis by down-regulating Bax and up-regulating Bcl-2 and obviously reduces the levels of IL-6, IL-1beta and TNF-alpha in serum, and in an animal model, 150-600mg / kg of the folium cortex eucommiae extract is continuously administrated for 21-30 days in an intragastric manner, so that the effect of preventing and treating adriamycin nephropathy is achieved. The traditional Chinese medicine composition can effectively relieve weight loss, reduce urine protein, serum creatinine and urea nitrogen, increase albumin and improve kidney pathological injury, and is suitable for relieving kidney toxicity in a prophylactic or therapeutic mode in subjects receiving adriamycin chemotherapy.

The invention relates to a cathepsin B sensitive fatty acid-adriamycin prodrug as well as albumin nanoparticles, a preparation method and application thereof, and belongs to the technical field of medicines. The cathepsin B sensitive fatty acid-adriamycin prodrug is a prodrug as shown in a formula (I), a geometric isomer thereof, and pharmaceutically acceptable salts, hydrates and solvates thereof, wherein n is equal to 0-14. The invention also relates to a combined albumin nanoparticle prepared by entrapping the cathepsin B sensitive fatty acid-adriamycin prodrug by using human / bovine serum albumin as a carrier. The albumin nanoparticles are small in particle size and uniform in form, have good placement stability and colloidal stability, can stably exist in systemic circulation and normal tissues, and release a parent drug adriamycin after being taken by tumor cells and hydrolyzed by cathepsin B; therefore, specific killing of tumor cells is realized without generation of serious toxic and side effects, and good clinical development prospects are achieved.

The invention provides a biological membrane fusion nano-micelle, a drug-loaded biological membrane fusion nano-micelle as well as a preparation method and application thereof, and belongs to the technical field of medicines. The biological membrane fusion nano-micelle comprises an elastin-like polypeptide nano-micelle, a cancer cell membrane coating the surface of the elastin-like polypeptide nano-micelle, L-arginine located between the elastin-like polypeptide nano-micelle and the cancer cell membrane, and a fat-soluble photosensitizer located between phospholipid bilayers of the cancer cell membrane. The biological membrane fusion nano-micelle can bypass a traditional endocytosis way, and the treatment effect can be improved; the hydrophilic and hydrophobic structure of the elastin-like polypeptide nano-micelle is utilized to facilitate encapsulation of fat-soluble chemotherapeutic drugs (such as rapamycin or adriamycin), and a fat-soluble photosensitizer (such as a photosensitizer IR780 or a photosensitizer ICG) can be embedded into a phospholipid bilayer of a cancer cell membrane by utilizing the hydrophobic effect of the elastin-like polypeptide nano-micelle. Cancer synergistic chemotherapy, photodynamic therapy and gas therapy can be realized.

The invention discloses an effective part of a pulse-activating decoction as well as an extraction and purification method and application thereof, and the extraction and purification method comprises the following steps: taking red ginseng, radix ophiopogonis and schisandra chinensis as raw materials, adding water for extraction, and freeze-drying to obtain freeze-dried powder; dissolving the freeze-dried powder with distilled water, loading the dissolved powder on a macroporous adsorption resin column, carrying out gradient elution with water and a 20% ethanol aqueous solution in sequence, and separating fractions Fr1-Fr8; the chromatographic characteristics of each fraction are analyzed by using a C18 chromatographic column through a liquid chromatograph, the fractions with the same chromatographic characteristics are combined, the fractions Fr1-Fr4 are combined into a component yf-1, the fraction Fr5 is combined into a component yf-2, and the component yf-2 is the effective part of the pulse-activating decoction. According to the effective part disclosed by the invention, toxic parts are removed, so that H9c2 cell injury caused by adriamycin can be more effectively and stably protected with lower toxicity, and the application of the component yf-2 in preparation of medicines for treating myocardial cell injury is prompted.

The invention discloses application of rehmannia D in preparation of a product for preventing and / or treating myocardial injury, and belongs to the technical field of medicines. The myocardial injury comprises myocardial injury induced by doxorubicin (DOX), and experiments prove that the rehmannia D can obviously improve the heart function decline caused by the DOX; the myocardial cell atrophy induced by DOX can be obviously inhibited; the level of myocardial tissue fibrosis induced by DOX can be obviously inhibited; the DOX-induced myocardial tissue oxidative stress level can be obviously inhibited; in addition, DOX-induced myocardial tissue DNA damage (gamma-H2AX is taken as a marker) can be obviously inhibited. The invention proves that the rehmannia glycoside D can be used as a novel treatment means to be applied to treatment of adriamycin-induced myocardial injury, and the risk of treatment interruption or heart failure due to cardiotoxicity caused by chemotherapy of a patient can be possibly reduced, so that the disease burden of the patient and the pressure of a medical system are relieved.

The invention discloses a construction method and application of an adriamycin-induced zebrafish osteoporosis-like model, and the construction method comprises the following steps: by utilizing the characteristics of transparency and rapid bone development of zebrafish embryos and juvenile fishes, selecting the zebrafish embryos of 2dpf, and culturing the zebrafish embryos to 6dpf in an adriamycin aqueous solution of 20 mu m, so as to obtain the adriamycin-induced zebrafish osteoporosis-like model. Therefore, the visual zebrafish osteoporosis-like model is efficiently constructed, juvenile fish bodies are transparent, imaging is visual, bone development changes can be observed in vivo in real time, and visual evaluation of bone development injuries is achieved. The built zebrafish osteoporosis-like model clearly shows the systematic inhibition effect of chemotherapy drugs on bone formation and mineralization, has the advantages of being short in building period, easy and convenient to operate, high in repeatability and sensitive to drug reaction, can be used for rapid dose screening and intervention experiments, and has good application prospects. The method has great application potential in research of pathogenesis of CIOP, screening of anti-osteoporosis drugs and evaluation of curative effect of the anti-osteoporosis drugs.

The invention belongs to the technical field of biological medicine, and discloses a construction method and application of a podocyte specific S1PR1 gene knockout mouse model. A podocyte specific S1PR1 knockout mouse is constructed through a Cre-LoxP system, and then an FSGS model is constructed through doxorubicin injection. And verifying the model by using urine detection, serum detection, histopathology detection and molecular mechanism detection. Research finds that S1PR1 expression decline causes POLR2A splicing abnormity and expression decline through down-regulation of Xab2, and podocyte senescence and FSGS progress are induced. According to the invention, a related model is constructed for the first time, the regulation effect of the S1PR1-Xab2-POLR2A pathway in podocyte senescence is disclosed, a reliable tool is provided for researching FSGS pathogenesis, the potential of S1PR1 as a therapeutic target is determined, and the S1PR1 can be used for screening drugs for treating FSGS and has important clinical transformation value.

The invention discloses a preparation method and application of a folic acid targeted multi-drug synergistic nano polymer prodrug, and belongs to the technical field of nano biomedical materials. The preparation method comprises the following steps: on the basis of a click reaction, crosslinking polyfunctional 2-methylglycerol tripropiolate with adriamycin and resveratrol to prepare a nano polymer prodrug BDR with an acid response characteristic; a folic acid targeting molecule FA-PEG-NH2 is efficiently grafted by utilizing a click reaction, so that the active targeting nano polymer prodrug BDRP with high selectivity and multi-drug synergism is prepared. Experiments find that pH-sensitive chemical bonds with tumor microenvironment dual stimulation response are introduced into poly-prodrugs, intelligent controlled release of chemotherapeutic drugs at tumor parts can be achieved, and the bioavailability is improved; fA-PEG-NH2 is further modified, so that the active targeting efficiency is improved, the poly-prodrug has better specificity, selectivity and biological safety on tumor cells, and the treatment effect on cervical cancer can be improved.

The application belongs to the technical field of medicine, and relates to preparation and application of a liposome prodrug overcoming adriamycin resistance. 2000 On the basis, the prodrug is loaded in a constructed targeted liposome (DSPE-PEG The preparation method is simple, the stability is good, high-efficiency drug loading and delivery are realized, and the liposome prodrug is stable, slow-released, safe, and the like. The liposome prodrug can target the folate receptor on the surface of a tumor, under the action of high-level GSH in a tumor cell, the disulfide bond is broken and BQR and DOX are released. BQR can induce tumor cell ferroptosis and hinder DNA repair, and can synergistically kill tumor cells with adriamycin while overcoming cell resistance to adriamycin. The liposome prodrug prepared in the application realizes targeted delivery of drugs, has good in-vitro anti-tumor activity, overcomes adriamycin resistance, and has a broad development prospect.

The invention relates to the technical field of biological medicines, and particularly discloses application of a short peptide MPM in preparation of a reagent or a medicine for treating liver injury and heart injury. The amino acid sequence of the short peptide MPM is shown as any one of SEQ ID NO: 1 to SEQ ID NO: 3. The oligopeptide MPM and the reagent for promoting the content of the oligopeptide MPM can be used for treating liver injury and heart injury, and particularly can be used for treating acetaminophen-induced liver injury and adriamycin-induced heart injury.

The invention discloses a doxorubicin chiral polyurethane delivery micelle as well as preparation and application thereof. The doxorubicin chiral polyurethane delivery micelle comprises a micelle carrier and doxorubicin, wherein the micelle carrier is formed by self-assembly of an amphiphilic polymer, and the doxorubicin is entrapped in the micelle carrier; the amphiphilic polymer comprises a hydrophobic chain segment and a hydrophilic chain segment which are covalently connected through a dynamic borate bond; the hydrophilic chain segment contains methoxy polyethylene glycol gallate; the hydrophobic chain segment comprises a hydrophobic chiral polyurethane main chain and a coumarin-phenylboronic acid conjugate covalently grafted to the hydrophobic chiral polyurethane main chain, and the hydrophobic chiral polyurethane main chain is formed by alternately connecting chiral binaphthol units and isophorone diisocyanate units; according to the doxorubicin chiral polyurethane delivery micelle, the water solubility of doxorubicin is improved, targeted release of doxorubicin can be achieved through pH and ROS response, side effects are reduced, and the affinity of cells to the doxorubicin chiral polyurethane delivery micelle is increased by using chiral binaphthol as a skeleton component.

The invention relates to application of an activating agent in promotion of uranium element discharge. Specifically, the activating agent is prepared from rifampicin, erythromycin, progesterone, aldosterone, bilirubin, cholate vinblastine, doxomicin, adriamycin, paclitaxel, bosentan, ambrisentan, digoxin, verapamil, tonavir, amprenavir, indinavir, hypericum perforatum juice, curcumin, atorvastatin beclomethasone, budesonide, divaricasone carbamazepine and caffeine. And phenytoin. The use dosage of the activating agent is 10 to 60 mg / kg. According to the method, the accumulation amount of uranium in important organs such as bones and kidneys can be remarkably reduced, so that the potential toxic influence on the key organs is reduced.

The invention belongs to the technical field of medicines, discloses a compound in radix salviae miltiorrhizae and application of the compound in preparation of a medicine for treating heart failure, and particularly relates to application of a compound DS-31 with a novel structure in radix salviae miltiorrhizae or pharmaceutically acceptable salt, ester or solvate of the compound DS-31 in preparation of a medicine for preventing and / or treating heart failure diseases. Pharmacological tests prove that DS-31 has a protective effect on myocardial cell injury caused by adriamycin; in addition, the compound has an obvious protection effect on adriamycin-induced heart failure mice, myocarditis and fibrosis are relieved, abnormal heart reconstitution and dysfunction are reversed, the action mechanism is related to recovery of myocardial cell mitochondrial energy supply, and the compound has the potential of being developed into anti-heart failure drugs.

The present invention discloses the role of Amuc_1100 in the preparation of drugs that alleviate doxorubicin cardiotoxicity. In vivo experimental results show that Amuc_1100 can effectively alleviate the toxic effects of the chemotherapy drug doxorubicin on the heart. By improving the homeostasis of the body and cardiac immune cells, reducing cell apoptosis in myocardial tissue, alleviating elevated myocardial enzymes, and enhancing left ventricular diastolic capacity and cardiac ejection fraction, it reduces the toxic side effects of the chemotherapy drug doxorubicin. It also improves the intestinal barrier function damage caused by doxorubicin chemotherapy. The present invention overcomes the current limitations on the clinical use of Dox and the drawbacks of existing chemotherapy cardioprotective drugs, while also solving the problem of preventing and treating the cardiotoxicity and intestinal side effects induced by Dox chemotherapy.